Siemens Health/€SHL
1D1W1MYTD1Y5YMAX
Capital at risk
About Siemens Health
Siemens Healthineers AG, listed under the ticker SHL, operates in the healthcare sector and is particularly known for its innovative medical technology. The company, a segment of the larger Siemens Group, specializes in diagnostic and therapeutic products and services, including medical imaging, laboratory diagnostics, and point-of-care testing. Founded in 1847 as part of Siemens AG, Siemens Healthineers was spun off as a separate entity in 2018, reflecting its focus on healthcare technology and services.
- Ticker
- €SHL
- Sector
- Health
- Primary listing
- XETRA
- Employees
- 74,300
- Headquarters
- Forchheim, Germany
- Website
- www.siemens-healthineers.com
Siemens Health Metrics
BasicAdvanced
€43B
19.66
€1.97
0.83
€1.00
2.58%
Price and volume
Market cap
€43B
Beta
0.83
52-week high
€49.78
52-week low
€32.84
Average daily volume
869K
Dividend rate
€1.00
Financial strength
Current ratio
1.162
Quick ratio
0.705
Long term debt to equity
59.962
Total debt to equity
78.296
Dividend payout ratio (TTM)
50.52%
Interest coverage (TTM)
7.96%
Profitability
EBITDA (TTM)
4,022
Gross margin (TTM)
39.02%
Net profit margin (TTM)
9.55%
Operating margin (TTM)
13.98%
Effective tax rate (TTM)
22.60%
Revenue per employee (TTM)
€310,000
Management effectiveness
Return on assets (TTM)
4.48%
Return on equity (TTM)
12.15%
Valuation
Price to earnings (TTM)
19.658
Price to revenue (TTM)
1.878
Price to book
2.28
Price to tangible book (TTM)
-9.05
Price to free cash flow (TTM)
16.687
Free cash flow yield (TTM)
5.99%
Free cash flow per share (TTM)
2.326
Dividend yield (TTM)
2.58%
Forward dividend yield
2.58%
Growth
Revenue change (TTM)
-0.92%
Earnings per share change (TTM)
2.32%
3-year revenue growth (CAGR)
2.33%
3-year earnings per share growth (CAGR)
11.62%
3-year dividend per share growth (CAGR)
1.72%
What the Analysts think about Siemens Health
Analyst ratings (Buy, Hold, Sell) for Siemens Health stock.
Analyst projections of the future price of Siemens Health stock.
Bulls say / Bears say
In Q3 FY2026, Siemens Healthineers reported a 15.6% year-on-year increase in adjusted EBIT to €1.101 billion and achieved an EBIT margin of 19.1%, prompting management to raise its full-year 2026 revenue growth guidance to 3.5–4.0%. (Reuters)
Q3 order intake outpaced revenue by 27%, highlighting resilient demand across the company’s core imaging and precision therapy businesses despite headwinds in diagnostics. (Reuters)
On April 30 2026, Siemens Healthineers secured a $60 million award from ARPA-H to develop photon flash radiotherapy technologies, underscoring its leadership in innovative cancer treatment solutions. (Aunt Minnie)
Siemens Healthineers cut its 2026 revenue growth forecast to 3.5–4.0% citing structural price resets and procurement policy changes in China’s diagnostics market, spotlighting ongoing headwinds in its Diagnostic division. (Reuters)
In Q1 FY2026, the company missed revenue expectations as currency headwinds, including a stronger euro, and diagnostic market weakness in China weighed on sales and constrained organic growth. (Reuters)
The planned spin-off of Siemens Healthineers from Siemens AG has been delayed to a shareholder vote in February 2027, prolonging strategic uncertainty and potentially dampening investor sentiment. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 25 Aug 2026.
Siemens Health Financial Performance
Revenues and expenses
Siemens Health Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing Siemens Health
AllEURGBPUSD
Fund name | Fund size | €SHL weighting |
|---|---|---|
iShares TecDAX€EXS2 | €645M | 11.06% |
iShares STOXX Europe 600 Health Care€EXV4 | €687M | 0.90% |
Amundi DAX III€DAX | €658M | 0.90% |
Amundi DAX II£DAXX | £572M | 0.85% |
iShares Core DAX€EXIC | €72M | 0.82% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.